On Oct 29, major Wall Street analysts update their ratings for $Inari Medical (NARI.US)$, with price targets ranging from $48 to $86.
Morgan Stanley analyst Kallum Titchmarsh maintains with a buy rating, and maintains the target price at $60.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and maintains the target price at $65.
Baird analyst David Rescott maintains with a buy rating, and maintains the target price at $67.
Needham analyst Michael Matson maintains with a hold rating.
Stifel analyst Mathew Blackman maintains with a hold rating, and maintains the target price at $50.
Furthermore, according to the comprehensive report, the opinions of $Inari Medical (NARI.US)$'s main analysts recently are as follows:
The firm estimates that Inari Medical achieved mid-to-high-teens growth in the US VTE market, indicating that the company is maintaining market share better than some anticipated. Furthermore, the firm supports the view of a more sustainable multiple expansion as the arguments from the 'bearish' perspective appear to be less convincing.
Here are the latest investment ratings and price targets for $Inari Medical (NARI.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
